Cart
sales@molnova.com
Growth Hormone Releasing Factor, GRF, (1 - 40), human
CAS No. ———
Growth Hormone Releasing Factor, GRF, (1 - 40), human( ——— )
Catalog No. M41194 CAS No. ———
Growth Hormone Releasing Factor, GRF, (1 - 40), human
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGrowth Hormone Releasing Factor, GRF, (1 - 40), human
-
NoteResearch use only, not for human use.
-
Brief DescriptionGrowth Hormone Releasing Factor, GRF, (1 - 40), human
-
DescriptionGrowth Hormone Releasing Factor, GRF, (1 - 40), human
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number———
-
Formula Weight4544.12
-
Molecular FormulaC194H317N61O63S
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Delphinidin 3-O-gala...
Delphinidin 3-O-galactoside
-
Bretazenil
Bretazenil is a GABAA benzodiazepine site partial agonist. Bretazenil shows an EC50 of 10 nM for recombinant α1β1γ2.
-
Burosumab
Burosumab(KRN23) is a human monoclonal antibody targeting fibroblast growth factor 23 (FGF23) for the treatment of cutaneous-skeletal hypophosphatemic syndrome (CSHS) and tumor-induced osteochondrosis.
